The combination of BRAF and MEK inhibition and anti-PD-1 is tolerable and has promising efficacy, which warrants further investigation into its use as melanoma therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Long, G. V. et al. J. Clin. Oncol. 36, 667–673 (2018).
Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).
Long, G. V. et al. Am. J. Clin. Oncol. 36, 9503–9503 (2018).
Hodi, F. S. et al. Lancet Oncol. 19, 1480–1492 (2018).
Ribas, A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0476-5 (2019).
Sullivan, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0474-7 (2019).
Ascierto, P. A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0448-9 (2019).
Robert, L., Ribas, A. & Hu-Lieskovan, S. Semin. Immunol. 28, 73–80 (2016).
Wilmott, J. S. et al. Clin. Cancer Res. 18, 1386–1394 (2012).
Frederick, D. T. et al. Clin. Cancer Res. 19, 1225–1231 (2013).
Hu-Lieskovan, S. et al. Sci. Transl. Med. 7, 279ra241 (2015).
Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. N. Engl. J. Med. 368, 1365–1366 (2013).
Minor, D. R., Puzanov, I., Callahan, M. K., Hug, B. A. & Hoos, A. Pigment Cell Melanoma Res. 28, 611–612 (2015).
Deken, M. A. et al. OncoImmunology 5, e1238557 (2016).
Rozeman, E. A. et al. Ann. Oncol. 29, mdy424-056 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.A.R. received travel support from MSD and NanoString. C.U.B. reports personal fees as a consultant advisor for Bristol-Myers Squibb, Merck Sharpe Dohme, Roche, Novartis, Lilly, Pfizer, GlaxoSmithKline, GenMab and Pierre Fabre and has received research grants from Bristol-Myers Squibb, Novartis, and NanoString, all paid to the institution (Netherlands Cancer Institute).
Rights and permissions
About this article
Cite this article
Rozeman, E.A., Blank, C.U. Combining checkpoint inhibition and targeted therapy in melanoma. Nat Med 25, 879–882 (2019). https://doi.org/10.1038/s41591-019-0482-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0482-7